Coronavirus: Ema starts Remdesivir quick evaluation

   The European Medicines Agency (Ema) has initiated a rapid procedure continuous data review study on the antiviral drug remdesivir in relation to the treatment of Covid-19. It is a procedure that Ema uses to speed up the evaluation of a promising experimental drug during a public health emergency, such as the current pandemic. However, Ema points out, "it is still too early to draw conclusions about the drug's risk-benefit balance."